Table 1.
Patient and tumor characteristics of the recurrent/metastatic cohort, sorted by the AR pathway activity score
| Pt no. | Gender | Tumor tissue | Tumor % | Age tissue (mo.) | AR | AR‐V7 | AR IHC | AR pathway activity | AKR1C3 | SRD5A1 | SRD5A2 | HER2 status | Genetic alterations* | ADT | Clinical response | PFS (mo.) | OS (mo.) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | T | 70 | 46 | 0.278 | 0.005 | 5.0 | 33.1 | 0.072 | 0.637 | 0.001 | Pos | None | LHRH + bica | PD | 3 | 29+ |
| 2 | F | N | 60 | 45 | 0.030 | 0.000 | 4.0 | 33.9 | 0.712 | 0.865 | 0.000 | Neg | TP53 | Bica | PD | 2 | 5 |
| 3 | M | T | 50 | 136 | 0.260 | 0.001 | 6.0 | 34.8 | 2.099 | 3.117 | 0.001 | Pos | TP53 | Bica | PD | 3 | 9 |
| 4 | M | T | 60–70 | 133 | 0.345 | 0.004 | 5.0 | 36.1 | 0.061 | 1.741 | 0.008 | Pos | TP53 and ERBB2 | Bica | PD | 2 | 12 |
| 5 | F | T | 70 | 73 | 1.476 | 0.015 | 6.0 | 36.2 | 0.148 | 0.953 | 0.001 | Neg | PTEN and TP53 | Bica | PD | 3 | 7 |
| 6 | M | T | 25 | 50 | 1.097 | 0.008 | 5.0 | 38.9 | 0.075 | 0.933 | 0.003 | Neg | PTEN and TP53 | Bica | SD >6 mo. | 6 | 12 |
| 7 | F | N | 60–70 | 15 | 1.522 | 0.129 | 6.0 | 41.3 | 0.017 | 1.212 | 0.000 | Neg | None | LHRH + bica | PD | 9 | 14+ |
| 8 | M | T | 80 | 80 | 0.009 | 0.000 | 4.0 | 42.7 | 0.023 | 0.669 | 0.001 | Pos | TP53 | Bica | PD | 0 | 0 |
| 9 | M | T | 80 | 38 | 0.615 | 0.021 | 3.0 | 43.2 | 0.707 | 1.111 | 0.021 | Pos | None | Bica | PD | 2 | 34+ |
| 10 | M | T | 70 | 8 | 5.169 | 0.737 | 6.0 | 43.6 | 2.313 | 9.646 | 0.000 | Neg | None | Bica | PD | 2 | 3+ |
| 11 | F | M (epidural) | 30 | 7 | 0.063 | 0.001 | 0.0 | 43.7 | 0.323 | 0.674 | 0.001 | Pos | HRAS and PIK3CA | LHRH + bica | PD | 0 | 10 |
| 12 | M | T | 70 | 61 | 1.409 | 0.006 | 5.0 | 44.3 | 0.332 | 2.854 | 0.001 | Neg | AKT1 and BRAF | Bica | SD >6 mo. | 18 | 40+ |
| 13 | M | T | 70 | 66 | 1.251 | 0.006 | 6.0 | 45.3 | 0.093 | 3.622 | 0.000 | Pos | TP53 and ERBB2 | Bica | PR | 27 | 56+ |
| 14 | F | T | 70 | 195 | 3.227 | 0.454 | 6.0 | 45.4 | 0.732 | 5.540 | 0.001 | Neg | HRAS and PIK3CA | Bica | PD | 1 | 13 |
| 15 | F | T | 60 | 131 | 0.414 | 0.009 | 2.0 | 45.6 | 0.521 | 0.927 | 0.000 | Neg | None | LHRH + bica | PD | 2 | 5 |
| 16 | F | T | 40 | 48 | 0.082 | 0.001 | 2.0 | 46.6 | 0.065 | 1.206 | 0.001 | Neg | None | LHRH + bica | PD | 1 | 25 |
| 17 | M | T | 70 | 27 | 0.605 | 0.006 | 6.0 | 46.7 | 0.461 | 0.919 | 0.000 | Neg | None | Bica | SD <6 mo. | 5 | 12+ |
| 18 | M | T | 70 | 47 | 9.105 | 0.309 | 6.0 | 47.9 | 1.385 | 8.000 | 0.000 | Neg | BRAF | Bica | PR | 6 | 40+ |
| 19 | M | T | 30 | 13 | 5.046 | 0.081 | 6.0 | 48.8 | 0.732 | 5.429 | 0.007 | Neg | None | Bica | PD | 2 | 2+ |
| 20 | M | T | 30 | 25 | 1.598 | 0.038 | 6.0 | 49.4 | 0.395 | 8.877 | 0.003 | Neg | None | Bica | PD | 3 | 17 |
| 21 | M | M (liver) | 80 | 91 | – | – | 6.0 | 50.4 | – | – | – | Neg | TP53# | Bica | PD | 1 | 7 |
| 22 | M | T | 70 | 88 | 1.057 | 0.005 | 5.0 | 51.9 | 0.174 | 2.099 | 0.003 | Neg | TP53 | Bica | PD | 1 | 11 |
| 23 | M | T | 60 | 66 | 0.578 | 0.005 | 6.0 | 52.0 | 0.186 | 0.905 | 0.001 | Pos | TP53 | Bica | SD <6 mo. | 5 | 33 |
| 24 | M | N | 80 | 7 | 4.666 | 0.196 | 5.5 | 52.7 | 0.993 | 0.827 | 0.013 | Pos | TP53 | Bica | PD | 2 | 6+ |
| 25 | M | T | 70 | 43 | 0.567 | 0.003 | 5.0 | 53.2 | 0.082 | 2.060 | 0.019 | Pos | None | LHRH + bica | SD >6 mo. | 9 | 18+ |
| 26 | M | T | 90 | 66 | 4.522 | 0.207 | 6.0 | 54.5 | 0.282 | 4.710 | 0.010 | Neg | PIK3CA | LHRH + bica | SD >6 mo. | 8+ | 13+ |
| 27 | M | T | 70 | 20 | 1.094 | 0.186 | 6.0 | 56.7 | 0.056 | 3.216 | 0.003 | Pos | None | Bica | PR | 5 | 18+ |
| 28 | M | T | 70 | 39 | 2.438 | 0.262 | 6.0 | 57.6 | 0.448 | 2.636 | 0.027 | Neg | HRAS and 2xPIK3CA | Bica | SD <6 mo. | 1 | 5 |
| 29 | M | M (skull base) | 90 | 154 | 3.287 | 0.068 | 6.0 | 61.8 | 9.590 | 33.988 | 0.004 | Neg | None | Bica | PR | 10 | 20 |
| 30 | M | N | 60 | 101 | 2.746 | 0.069 | 6.0 | 65.6 | 1.148 | 21.472 | 0.008 | Neg | HRAS and PIK3CA | Bica | PR | 14. | 44 |
Abbreviations: #, because of low DNA yield other mutations could have been missed; *, specific mutations are listed in Supporting Information Table S3; +, ongoing PFS/OS; ADT, androgen deprivation therapy; AKR1C3, aldo‐keto reductase family 1 member C3 gene expression; AR IHC, immunohistochemical androgen receptor expression; AR, androgen receptor gene expression; AR‐V7, androgen receptor splice variant 7 gene expression; bica, bicalutamide; F, female; LHRH, luteinizing hormone‐releasing hormone agonist; M, distant metastasis; M, male; mo., months; N, lymph node metastasis in neck; OS, overall survival; PD, progressive disease; PFS, progression‐free survival; PR, partial response; SD, stable disease; SRD5A, steroid 5 alpha‐reductase gene expression; T, primary tumor.